Factor This Power Engineering
Live Events
DTECH® Events
POWERGENâ¢
Calendar
Webinars
Podcasts
Contribute Content
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Smart Grids
Transmission
Hydropower
Dams & Civil Structures
Small Hydropower
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Project Development
Tariffs
Electric Vehicles
EV Charging
Vehicle to Grid
Subscribe
Solar
Community
Residential
Utility Scale
Wind Power
Offshore
Turbines & Equipment
Power Grid
Distribution
Grid Modernization
Microgrids
Outage Management
Transmission
Smart Grids
Hydropower
Dams & Civil Structures
Small Hydro
Technology & Equipment
Tidal & Wave Energy
Energy Storage
Battery
Long Duration
Pumped Storage
Business
Finance
Policy & Regulation
Electric Vehicles
EV Charging
Vehicle to Grid
Factor This: Power Engineering
Live Events
DISTRIBUTECH®
Podcasts
Webinars
Calendar
Contribute Content
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Glaukos Corporation Common Stock
(NY:
GKOS
)
123.09
+2.85 (+2.37%)
Streaming Delayed Price
Updated: 12:27 PM EST, Jan 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Glaukos Corporation Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
↗
March 09, 2023
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.
Via
Benzinga
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
February 27, 2023
From
Glaukos Corporation
Via
Business Wire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
↗
February 23, 2023
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose...
Via
Benzinga
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Glaukos Corporation
Via
Business Wire
Earnings Preview For Glaukos
↗
February 21, 2023
Via
Benzinga
Analyst Expectations for Glaukos's Future
↗
December 28, 2022
Via
Benzinga
10 Analysts Have This to Say About Glaukos
↗
December 28, 2022
Via
Benzinga
What 10 Analyst Ratings Have To Say About Glaukos
↗
December 28, 2022
Via
Benzinga
Glaukos Announces Participation in the Citi Healthcare Conference
February 15, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
February 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
7 Analysts Have This to Say About Glaukos
↗
December 12, 2022
Via
Benzinga
Analyst Ratings for Glaukos
↗
December 12, 2022
Via
Benzinga
Where Glaukos Stands With Analysts
↗
December 12, 2022
Via
Benzinga
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 28, 2022
From
Glaukos Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
↗
December 22, 2022
Via
Benzinga
Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
↗
December 22, 2022
This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE).
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
↗
December 19, 2022
Via
Benzinga
What 4 Analyst Ratings Have To Say About Glaukos
↗
November 03, 2022
Analysts have provided the following ratings for Glaukos (NYSE:GKOS) within the last quarter:
Via
Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
↗
December 19, 2022
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5. Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
↗
December 12, 2022
Via
Benzinga
Needham Says Recent Launches To Drive Market Share Recovery For This Eye-Focused MedTech Stock
↗
October 04, 2022
Via
Benzinga
Glaukos Announces Participation in the Stephens Annual Investment Conference
November 07, 2022
From
Glaukos Corporation
Via
Business Wire
Kellogg, Palo Alto Networks, Roku And Other Big Losers From Thursday
↗
November 04, 2022
U.S. stocks closed lower on Thursday, with the Dow Jones dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session.
Via
Benzinga
Glaukos Corporation Announces Third Quarter 2022 Financial Results
November 02, 2022
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
October 12, 2022
From
Glaukos Corporation
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
↗
September 29, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
September 28, 2022
From
Glaukos Corporation
Via
Business Wire
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
↗
September 08, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
